The updated labeling will now include findings from the TRAVERSE trial, which determined no increased risk of adverse cardiovascular outcomes in men using testosterone for hypogonadism, according to a Feb. 28 news release from the agency.
However, the FDA will maintain the “limitation of use” language for age-related hypogonadism and remove previous box warning language about cardiovascular risks.
In addition, based on postmarket ambulatory blood pressure studies, the FDA is requiring new warnings about increased blood pressure for all testosterone products and product-specific information added for those with completed studies.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.